BioSpace News Archive

Business

George Medicines appoints Stefan König as Chief Executive Officer

London, UK, 3 June 2021 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, announces the appointment of Stefan König as Chief Executive Officer.

June 3, 2021
·
5 min read
BioMidwest

Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly’s Preventive and Acute Treatment Portfolio at AHS 2021

- Nearly half of people with migraine hesitated to seek care, choosing self-management and out of concern their disease would not be taken seriously, based on new findings from OVERCOME (U.S.), the largest population-based study of its kind

June 3, 2021
·
23 min read
Bio NC

BioCryst Launches ORLADEYO™ (berotralstat) in Germany

BioCryst Pharmaceuticals, Inc. announced that oral, once-daily ORLADEYO™ is now available for patients with a prescription in Germany.

June 3, 2021
·
4 min read
Business

OrthoPediatrics Corp. Completes Senior Leadership Transition with Appointment of David Bailey as Chief Executive Officer

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the completion of the senior leadership transition, with David Bailey succeeding Mark Throdahl as Chief Executive Officer.

June 3, 2021
·
2 min read
Germinator and AREV Nanotech Brands Inc. Sign Distribution Agreement to Provide the Genesis Platform of Surface Disinfection to Global Public Health Commodity Procurement Programs

The partnership will help serve a dire need for surface disinfectant treatments to prevent the spread of highly infectious diseases to vulnerable populations in developing nations

June 3, 2021
·
7 min read
Genetown

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - June 03, 2021

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the following investor conferences in June

June 3, 2021
·
1 min read
Drug Development

Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Confirmatory Phase 3 Study, RALLY, Ongoing with Interim Analysis Expected in Third Quarter 2021

June 3, 2021
·
8 min read
Drug Development

Innovation Pharma Completes Enrollment in Phase 2 Clinical Trial for COVID-19

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announced that it has achieved full patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients.

June 3, 2021
·
5 min read
Microbix Secures Third Ontario Manufacturing SiteLeasing and Equipping 10,000 Square Foot Building Adjacent to Current Sites

Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has secured a third manufacturing site in Mississauga, Ontario, by way of a long-term lease agreement for a property adjacent to its two current sites.

June 3, 2021
·
5 min read
Biotech Bay

4D Molecular Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 2:30 p.m. PT.

June 3, 2021
·
1 min read